Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Bowman Cox

Executive Editor

Washington, DC
Bowman Cox leads the Pink Sheet's coverage of pharmaceutical manufacturing quality issues. He writes and edits articles on the challenges and opportunities that developments in science, technology and regulatory policy pose to drug manufacturers and their quality organizations.

Latest From Bowman Cox

US Forming Industry Consortia To Prepare For Future Pandemics And Global Supply Chain Disruptions

HHS agencies look to build on COVID-19 experience by developing quicker public/private responses to pandemics and supply chain threats.

Manufacturing Market Intelligence

BARDA Lays Out Vision For Next Pandemic: Vaccines For The US Within 130 Days

Federal agency seeks dialogue with industry on how to enable surge capacity for pandemic vaccines without cutting back on other production.One key factor: workforce development.

Vaccines Manufacturing

As Emergent Partnership Dissolves, BARDA Looks To Revamp Post-COVID Pandemic Preparedness

BARDA terminates CIADM contract in wake of vaccine cross-contamination incident, begins discussion with industry about next steps for rapid pandemic response capabilities.

Coronavirus COVID-19 Manufacturing

How US FDA Wants Pharmaceutical Production Volumes Reported For Drug Shortage Prevention

Monthly data are expected in annual reports on listed drugs and active ingredients from every registered site, starting in February.

FDA Guidance Documents

How US FDA Wants Pharmaceutical Production Volumes Reported For Drug Shortage Prevention

Monthly data are expected in annual reports on listed drugs and active ingredients from every registered site, starting in February.

Manufacturing Compliance

Fewer Observations, Shift In Emphasis Seen In FDA's Pandemic-Reduced Inspections

US agency mostly saw less of the same when it scaled back inspectional activity during COVID-19, but observed more training and equipment issues.

Manufacturing Quality
See All
UsernamePublicRestriction

Register